PDGFRA and gastrointestinal stromal tumor: While there was no apparent effect on PFS in patients without PDGFRα mutations, PDGFRα-mutant GIST patients (all with D842V mutations) treated with olaratumab had longer disease control compared with historical data for this genotype.